Cetuximab Activity in Dysplastic Lesions of the Upper Aerodigestive Tract

BACKGROUND: High risk head and neck mucosal premalignancy has a malignant conversion rate of up to 40%, despite adequate surgical therapy. Epidermal Growth Factor Receptor (EGFR) blocking agents, including cetuximab, have shown activity in head and neck squamous cell carcinoma (HNSCC) and have poten...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oral Oncol
Main Authors: Khan, Zubair, Epstein, Joel B, Marur, Shanthi, Gillespie, M Boyd, Feldman, Lawrence, Tsai, Hua-Ling, Zhang, Zhe, Wang, Hao, Sciubba, James, Ferris, Robert, Grandis, Jennifer R, Gibson, Michael, Koch, Wayne, Tufano, Ralph, Westra, William, Tsottles, Nancy, Ozawa, Hiroyuki, Chung, Christine, Califano, Joseph A
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7751887/
https://ncbi.nlm.nih.gov/pubmed/26686755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2015.11.016
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares